Related Experiment Video
Updated: Jul 4, 2026
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
Is the Satisfaction with Cancer Information Profile (SCIP) valid for tailoring information for patients with head and
Matthew C Hankins1, Carrie D Llewellyn
1Department of Primary Care & Public Health, Brighton & Sussex Medical School, Brighton, UK. m.c.hankins@bsms.ac.uk
Background:
The Satisfaction with Cancer Information Profile (SCIP) has previously been shown to be a valid and reliable measure responsive to changes in patient satisfaction over time. It has been suggested that the SCIP might be used to guide the tailored provision of treatment information to patients with head and neck cancer but for this purpose the discrimination of the SCIP, not its responsiveness, should be assessed. This paper assesses whether the SCIP is valid as a discriminative measure suitable to guide tailored information.
Methods:
The SCIP comprises two parts (SCIP-A and SCIP-B). The discrimination of both parts was explored in a UK sample of 82 newly diagnosed patients with head and neck cancer. Principal components analysis (PCA) was first used to explore the factor structure of the SCIP-A and SCIP-B: discrimination analyses were then conducted at the level of full scale, subscale and item.
Results:
Principal components analysis revealed a coherent three-factor solution for the SCIP-A and a single factor for SCIP-B. Both parts of the SCIP proved to be discriminating at the full scale level (SCIP-A Delta = 0.92; SCIP-B Delta = 0.90). The SCIP-A also proved to be discriminating at the subscale level (Delta = 0.85 to 0.89). For the SCIP-A there was wide variation in the discrimination of individual items, confirming its potential to tailor information at the item level. For the SCIP-B, responses to most items indicated uniform satisfaction, suggesting that it would not be useful for tailoring information at the item level.
Conclusion:
The SCIP-A has been shown to be a valid discriminative measure and should prove suitable for tailoring treatment information at the level of item, subscale and total scale score. The SCIP-B, while a discriminating measure of total satisfaction, comprises too uniform a set of indicators of patient satisfaction to make it useful for tailoring information at the item level. Overall, the SCIP is valid as a measure of overall satisfaction with information about treatment and as a guide to tailoring such information.
Related Concept Videos
01:21Cancer Survival Analysis
01:27Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's cancer...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...